Sodan

Quick links to important sections

Sodan

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sodan

Sodan is a single-ingredient pharmaceutical preparation whose active component is Ursodiol, primarily classified as a Bile Acid Preparation and a Gastrointestinal Agent. This medication is designed to manage the delicate chemical balance within the biliary system by altering the composition of bile. Sodan is typically supplied as a prescription-only (Rx-only) medication.


Quick Facts

Property Description
Active ingredient Ursodiol (Ursodeoxycholic Acid, UDCA)
Form Capsule or Tablet (Oral dosage form)
Pharmacological class Bile Acid Preparation (ATC: A05AA02)
Common use Gallstone solubilizing agent and Liver Protectant
Origin Naturally-occurring (Secondary Bile Acid)

What is Sodan and What Class Does it Belong To?

Sodan is a Bile Acid Preparation that belongs to the broader class of Gastrointestinal Agents, functioning as a gallstone solubilizing agent. In the Anatomical Therapeutic Chemical (ATC) classification system, Ursodiol is categorized under the code A05AA02. This classification identifies the drug's role in therapeutic areas specifically related to bile and liver function. This single-ingredient product is prepared for oral administration in solid oral dosage forms, typically a capsule or a tablet, and is consistently positioned for use in adult patient groups.


Composition: Is Ursodiol a Natural Substance?

The active substance in Sodan, Ursodiol (Ursodeoxycholic Acid or UDCA), is a naturally-occurring secondary bile acid found in small amounts within the human bile acid pool. Its chemical structure, C24H40O4, makes it a highly hydrophilic compound, which is a key distinction from other more common and potentially toxic endogenous bile acids. Ursodiol has the property of decreasing cholesterol secretion and works by reducing cholesterol content in the bile.


What is the General Purpose of Bile Acid Preparations?

The general purpose of Sodan is to stabilize the bile environment by acting as a liver protectant and managing the saturation of cholesterol in bile. This mechanism is used for managing cholesterol deposits in the biliary system. The preparation achieves this by reducing the secretion of cholesterol from the liver into the bile and displacing potentially harmful, toxic bile acids with the milder, more hydrophilic Ursodiol. By helping to maintain a fluid and healthy bile composition, the drug supports the overall function of the body's gastrointestinal system and bile ducts, preventing the conditions that lead to deposit formation.

What side effects are possible with Sodan?

Possible side effects and safety information

The safety profile of Sodan is established through official regulatory documentation, detailing adverse reactions by frequency and physiological system. This medicine is associated with risks predominantly affecting the central nervous system, reflecting its specialized administration route.


Serious Adverse Reactions

Regulatory labeling documents several serious adverse reactions, primarily linked to the central nervous system. These include myelitis (inflammation of the spinal cord) and radiculitis (nerve root irritation), aseptic meningitis, and conditions related to increased pressure, such as papilledema (optic nerve swelling) and elevated intracranial pressure.


Common and Very Common Adverse Reactions

Adverse reactions classified as Very Common (ge 10% of participants) are frequently reported. These include general systemic effects such as fatigue and pyrexia (fever), alongside musculoskeletal effects like myalgia (muscle pain) and arthralgia (joint pain). Changes in laboratory parameters are also very common, specifically an increased white blood cell count and increased protein in the cerebrospinal fluid.

Reactions classified as Common (ge 1% to <10%) include papilloedema, myelitis, radiculitis, and aseptic meningitis. The official safety profile notes that non-serious pyrexia has been observed with repeat administration during long-term studies.


Specific Safety Considerations

Official prescribing information indicates that data are insufficient to evaluate the drug-associated risks of adverse developmental outcomes if used during pregnancy or to determine if the medicine is present in human milk during lactation. Due to the association of this drug class with renal toxicity, regulatory documents suggest the consideration of urine protein testing if clinically warranted.

Overdose and Emergency Response

Overdose and When to Seek Help

Taking more Sodan than prescribed, especially when combined with other Central Nervous System (CNS) depressants like alcohol or benzodiazepines, carries the risk of a severe, life-threatening overdose.

Overdose on this substance is associated with profound CNS depression. The official documented presentations and symptoms include:

  • Slowed or Stopped Breathing (Respiratory Depression)
  • Loss of Consciousness or Coma
  • Seizures
  • Extreme Drowsiness or Unresponsiveness
Overdose Risk Factors Associated Consequences
Ingestion of amounts larger than prescribed Life-threatening symptoms and death
Concurrent use with alcohol or other CNS depressants (e.g., sedating antipsychotics, opioid analgesics) Increased risk of respiratory depression and death

When to Seek Immediate Medical Attention

An overdose is an emergency. If you or someone else experiences any of the life-threatening symptoms listed, or if a known excessive dose has been taken, you must seek emergency medical treatment immediately.

Caregivers and patients should be aware of critical signs such as unusual dizziness, extreme sleepiness, or slowed, difficult breathing as warning signs. The onset of unresponsiveness or seizures requires immediate emergency response.

Therapeutic Uses of Sodan

Quick Facts

  • Sodan is a treatment option for patients diagnosed with amyotrophic lateral sclerosis (ALS).
  • It is specifically indicated for those with ALS associated with a mutation in the superoxide dismutase 1 ( SOD1) gene.

What Sodan Treats: Main Uses and Benefits

Sodan is a medication used to manage amyotrophic lateral sclerosis ( ALS) in adult patients who have a confirmed mutation in the SOD1 gene. This specific genetic form of ALS is a progressive neurodegenerative condition that impacts the nerve cells controlling voluntary muscle movement. Sodan is used to address this underlying cause of the disease.

Treatment has demonstrated a reduction in plasma neurofilament light chain ( NfL) concentrations in treated individuals. This reduction in the NfL biomarker is associated with a potential for clinical benefit in patients with this form of ALS. The medication provides a therapeutic approach for a rare subset of ALS cases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sodan?

The population eligibility for Sodan (Tofersen) is narrowly defined by regulatory authorities, focusing on specific genetic criteria and patient conditions.

Eligible Population

Sodan is indicated only for adult patients with amyotrophic lateral sclerosis (ALS) who have a confirmed mutation in the superoxide dismutase 1 (SOD1) gene.


Non-Eligible and Restricted Populations

Classification Regulatory Requirement/Restriction
Absolute Contraindication Patients with known hypersensitivity to the active substance or its excipients must not use this medicine.
Age Restriction Use in pediatric patients (below 18 years) is not established as safety and effectiveness have not been demonstrated.
Organ Impairment The medicine has not been studied in patients with severe renal impairment or hepatic impairment (liver function problems).
Pregnancy Use is not recommended during pregnancy. Women of childbearing potential are advised to use effective contraception.
Lactation A risk to the newborn cannot be excluded; the regulatory label advises a decision be made to discontinue either breastfeeding or therapy.

What should I know about interactions with other medicines?

Sodan's official interaction profile is characterized by a low potential for systemic drug-drug interactions, a factor related to its specialized route of administration (intrathecal injection). This administration route results in minimal systemic exposure, limiting the potential for pharmacokinetic interaction compared to many orally administered medicines. The information presented here is based strictly on government regulatory documents.

Official Interaction Statements

According to the official prescribing information, Sodan is formally classified as not an inducer or inhibitor of CYP450-mediated oxidative metabolism. This regulatory determination is essential, as the CYP450 enzyme system is responsible for the clearance of many co-administered medicines. The confirmation that Sodan does not interfere with this system means that it is not expected to alter the systemic exposure or clearance of co-administered drugs that rely on these metabolic pathways.

  • No specific drug-drug or drug-substance combinations are explicitly prohibited due to a specific systemic interaction risk documented in the regulatory label.
  • No mandatory timing requirements are documented for separating the administration of other medicines from Sodan.
  • No interactions with food, alcohol, or herbal products are officially documented in the prescribing information.

Connection to the Overall Interaction Profile

Regulatory documents define the product’s interaction structure primarily by stating the absence of common systemic pharmacokinetic interactions, specifically confirming Sodan is not a CYP450 enzyme modulator. This official regulatory statement means that Sodan is not expected to systemically affect the exposure or clearance of co-administered medicines that are substrates of these enzymes, nor is it expected to have documented interactions with food or alcohol.

Mechanism of Action

How Sodan Works — Mechanism of Action

Ursodiol acts on the cholesterol homeostasis pathway through two distinct mechanisms: it inhibits the fractional absorption of cholesterol in the intestine and suppresses its secretion from hepatocytes into the bile. This dual action significantly reduces the cholesterol saturation index of the bile, creating an environment where existing solid cholesterol deposits can be slowly solubilized back into the fluid bile.

Simultaneously, the drug reprograms the bile acid pool via competitive displacement, replacing more hydrophobic, detergent-like endogenous bile acids with the hydrophilic Ursodiol. This alteration reduces the detergent-like physical and chemical properties of the bile acid mixture. Ursodiol also stabilizes the cellular membranes of hepatocytes and cholangiocytes by incorporating itself into the lipid bilayer, blocking pro-apoptotic signaling pathways. The final mechanism is enhanced choleretic action—a direct stimulation of fluid and bicarbonate secretion from cholangiocytes, leading to an increased volume of bile flow and the movement of bile components through the biliary tract. This mechanism is constrained, however, and requires an unobstructed biliary tract to exert its physiological effect.

Dosage and Administration Information

Instruction Map: How to use Sodan — Administration Guidelines

Parameter Guideline
Route of administration Oral administration via capsule, tablet, or liquid suspension.
Dosing schedule Dosage is primarily weight-based for therapeutic use: 13–15 mg/kg of body weight per day for Primary Biliary Cirrhosis (PBC), or 8–10 mg/kg per day for gallstone dissolution.
Timing in relation to meals (if applicable) The medication is typically administered with food or a meal.
Preparation requirements (if applicable) Scored 500 mg tablets may be broken in halves to achieve the prescribed dose; the segments must be swallowed whole with water and not chewed.
Age-group administration rules Pediatric: Dosing for specific liver disorders is weight-based (e.g., 20 mg/kg/day) in divided doses. Older Adults: No specific age-related dose adjustments are mandated in the adult dosing information.
Missed-dose rules If a scheduled dose is missed, patients are instructed not to take a double quantity to compensate.
Special procedural conditions Half-tablets, once broken, should be used within a limited period (e.g., 28 days) to maintain integrity.

Instruction Classifications (High-Level)

Classification Guideline
Administration method type Oral
Frequency pattern Divided Daily Use (typically 2 to 4 times per day).
Use-context constraints Treatment course is finite (up to 2 years for gallstone dissolution) or indefinite (for chronic PBC management).

Resulting Procedural Structure

Step sequence:

  • Establish the correct total daily dose based on body weight.
  • Divide the total daily amount into 2 to 4 portions for administration.
  • Administer each portion with food.

Connection to the overall use protocol (2–4 sentences): The usage protocol describes administration by requiring a precise, weight-based daily amount to be divided across the day, ensuring consistent exposure. The instruction to take the medicine with food defines a condition for use. This protocol is further structured by defining the overall duration of use as either a fixed course or a long-term commitment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sodan (Ursodiol)

The following overview describes the structure of official research and the patterns observed in studies involving Sodan's active ingredient, Ursodiol, without offering clinical guidance or making claims about individual outcomes.


Evidence for Use in Primary Biliary Cholangitis (PBC)

Research exploring the compound for Primary Biliary Cholangitis (PBC) relies on Randomized Controlled Trials (RCTs) and extended-duration observational cohort studies. Researchers monitored specific outcomes related to systemic or functional imbalance, such as physiological strain reflected by liver biochemistry measurements and factors related to the potential need for a liver transplant.

The findings describe patterns observed in the studies that are related to shifts in measured liver enzyme levels over the treatment period. Long-term observational evidence suggests an association with patterns related to the timeline of disease progression in observed populations. However, earlier comprehensive analyses of the RCTs explored patterns related to long-term outcomes, including observed mortality, and described mixed findings when that outcome was considered as the sole primary endpoint.


Evidence for Gallstone Dissolution

Research on using Sodan for gallstone dissolution involves Randomized Controlled Trials that compared it to a placebo or other options. Study outcomes primarily focused on assessing the rate of complete dissolution of the stones, as tracked using imaging techniques like ultrasound. Studies reported that complete gallstone dissolution was observed in some studies that examined specific populations studied. Studies indicate that the radiological outcomes observed were highly contingent on the initial composition and size of the stones.


What is Still Uncertain About Sodan: Research Gaps and Study Limitations

While evidence exists for specific populations, the evidence quality varies across studies. For example, for PBC, the certainty that shifts in biochemical markers translate directly into long-term patient status for all groups remains low. Data for certain groups remain insufficient, particularly for patients with advanced stages of PBC. Furthermore, research provides context but not individual predictions for gallstone dissolution, and the sample sizes were modest in some earlier trials. Therefore, evidence is limited in defining the role of Sodan in some specific scenarios, and ongoing research is still emerging to fill these gaps.

Frequently Asked Questions (FAQ)

Common questions about Sodan (FAQ)

Q: How does Sodan affect my sleep patterns?

Official product information, based on clinical studies, reports that insomnia (difficulty sleeping) is a potential side effect, though it is not classified among the most frequent reactions. Certain sleep disorders have also been reported with unknown frequency in some patient populations. If sleep issues occur, patients may find relevant information about these side effects described in the regulatory documents.

Q: What is the shelf life of Sodan?

The exact shelf life of the unopened product is specific to the manufacturer and batch. This date, known as the expiration date, is listed directly on the container. The expiration date defines the time period during which the product is expected to remain stable and potent when stored under the specified conditions (such as refrigeration).

Q: Do I need to take Sodan at a specific time of day?

According to official administration instructions, the total daily amount of this medication is meant to be taken in divided doses, typically 2 to 4 times per day, and always with food. While a specific time of day (like morning or night) is not mandated, the goal is to consistently take the total daily amount in divided doses, and patients are usually advised to follow the frequency and timing instructions provided by their prescriber.

Q: Do children or teenagers commonly take Sodan?

Regulatory bodies generally approve this medication for use in adult patients. For pediatric patients (children and teenagers), the safety and effectiveness have not been fully established for all conditions. However, the active ingredient is sometimes used by prescribers for certain liver conditions. This may be considered an off-label use (a use not specifically approved by the FDA), which is a clinical decision made by a healthcare professional.

Q: Can Sodan be taken with multivitamins or supplements?

Official interaction information specifically cautions that certain substances, such as aluminum-based antacids and estrogen-containing supplements (like some oral contraceptives), may interfere with the drug's absorption or effectiveness. While general multivitamins are not listed as a prohibited interaction, information about any supplement, especially those containing cautioned ingredients, can be reviewed with a healthcare professional.

Q: Do patients need special monitoring while on Sodan?

Yes, regulatory documents describe the need for ongoing monitoring. The official prescribing information recommends that liver function tests (blood tests checking liver enzymes) should be monitored regularly, particularly when starting treatment. This monitoring is typically done monthly for the first few months and then every six months thereafter to ensure consistent health tracking.

Q: How quickly should I expect Sodan to start working?

The therapeutic effect of Sodan is generally not immediate. For example, studies related to gallstone dissolution indicate that therapy often requires months of continuous treatment. Official data show that the concentration of the active ingredient in the bile, which is necessary for the drug to work, reaches a steady level in the body after about three weeks of repeated daily dosing.

Q: Does Sodan cause weight gain or weight loss?

The regulatory documents list both unusual weight gain and weight loss among the reported side effects in patient populations. However, the frequency of these weight changes is not known or is considered less common. Rapid or unexplained weight changes are examples of effects that patients may review with their prescribing professional.

Q: Is Sodan known to cause mood changes?

Official reports on the side effect profile include anxiety and depression among the listed adverse reactions that affect the central nervous system. These are not classified as the most common side effects, but they are recognized by regulatory bodies as potential effects observed in some patients.

Q: Is there a generic version of Sodan available?

Yes. The active ingredient in Sodan, which is called Ursodiol, is available as a widely used generic prescription product. Official regulatory resources confirm that generic versions contain the same active ingredient and are required to meet comparable quality and efficacy standards.

Q: How long does Sodan stay in your system after stopping it?

According to the drug's pharmacological profile, once you stop taking the medication, the concentration of the active ingredient in the body's bile naturally decreases. Official data indicate that its concentration falls to about 5% to 10% of its working level approximately one week following the last dose.

Q: Does taking Sodan affect my ability to drive or operate machinery?

Regulatory information from official prescribing documents states that this medication has no or negligible influence on a person's ability to drive or operate heavy machinery safely. This is an official determination regarding the drug's effect on cognitive and motor functions.

Q: Is Sodan considered a controlled substance?

No. Major regulatory agencies, including the U.S. Drug Enforcement Administration (DEA) and national health authorities, have not classified the active ingredient, Ursodiol, as a controlled substance. This means it is not associated with abuse or dependence potential.

Q: Is the side effect of dry mouth common with Sodan?

Dry mouth is a known symptom associated with the underlying conditions this medication often treats, but it is not explicitly listed in the major categories of the drug's adverse reactions. Official regulatory documents do not report dry mouth as one of the common side effects of Sodan itself.

Q: Is it true that Sodan has a 'Black Box Warning' (descriptive/factual)?

No. A 'Black Box Warning' is the strongest safety warning placed by the FDA on a prescription product when there is reasonable evidence of a serious hazard. The official U.S. FDA prescribing information for the active ingredient in Sodan does not contain a Boxed Warning.

Q: How often do I need to see my doctor while taking Sodan?

The official product information, which details the required monitoring, suggests that blood tests for liver function should be conducted every few months to track progress and assess liver health. This is particularly important during the first few months of treatment for conditions like gallstones.

Q: What is the risk of dependence or addiction with Sodan (factual description)?

Regulatory bodies and drug classification systems do not recognize the active ingredient in Sodan as having any potential for abuse or dependence. Therefore, the medication is not associated with a risk of addiction.

Q: Are headaches a frequent issue reported by Sodan users?

Yes. According to clinical trial data summarized in regulatory documents, headache is considered a 'Very Common' side effect. It has been reported with frequencies approaching 25% of participants in some clinical trials.

Q: Is Sodan typically covered by insurance?

Yes. The generic version of the drug, Ursodiol, is a common prescription product. As a result, it is typically included in the formularies of most major insurance plans. However, the specific cost and coverage amount will depend on your individual plan details and deductible status.

Q: What is the typical time frame for seeing the full effect of Sodan?

The time frame varies significantly depending on the condition being treated. For gallstone dissolution, studies indicate that complete dissolution may require continuous treatment for up to two years. In clinical studies for gallstone dissolution, observing a partial positive response within the first six months has been associated with a higher chance of eventual dissolution.

Q: Can Sodan affect birth control pills?

Yes, official prescribing information notes a potential interaction. Certain oral contraceptives (birth control pills) that contain estrogen may counteract the effect of this medication. This interaction may be relevant because estrogen can affect the chemical balance in the bile, which could oppose the intended therapeutic action of Sodan.

Q: Why does Sodan require a prescription?

The medication is classified as prescription-only (Rx-only) because it is intended to address conditions that require professional medical diagnosis and management. Its use typically involves a need for regular professional monitoring, such as specific blood tests, as defined by the prescribing information.

How should Sodan be stored and disposed of?

Storage & Disposal Map: How to Store and Dispose of Sodan — official regulatory information

Category Regulatory Requirement
Labeled Storage Temperature Store refrigerated at 2 C to 8 C (36 F to 46 F). Do not freeze.
Light/Moisture Protection Store in the original carton to protect from light.
Handling Requirements Do not shake the vial. Allow the refrigerated vial to warm to room temperature (25 C or 77 F) prior to administration without using external heat sources.
Stability After Preparation Once the solution is drawn into the syringe, it must be administered immediately (within 4 hours of removal from the vial); otherwise, it must be discarded.
Packaging Rules Inspect the solution visually; do not administer if particles are observed or the liquid is not clear and colorless to slightly yellow.
Child-Safety Storage Keep this medicine out of the sight and reach of children.
Disposal Instructions Any unused contents of the single-dose vial must be discarded. Dispose of the product and all associated waste material in accordance with local requirements.
Environmental Restrictions Disposal should not be via wastewater or household waste.

The official storage profile mandates maintaining the product within a controlled cold chain (2 C to 8 C) and requires protection from freezing and light, using the original carton. Stability is time-constrained; pre-use inspection is mandatory to ensure solution integrity. As a single-dose product, any unused medicine must be discarded and handled according to local medicinal waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sodan found in:

A-Z Index: